title: Immune responses to O-specific polysaccharide and lipopolysaccharide of Vibrio cholerae O1 Ogawa in adult Bangladeshi recipients of an oral killed cholera vaccine and comparison to responses in patients with cholera.
abstract: Protective immunity to cholera is serogroup specific, and serogrouping is defined by the O-specific polysaccharide (OSP) of lipopolysaccharide (LPS). We characterized OSP-specific immune responses in adult recipients of an oral killed cholera vaccine (OCV WC-rBS) and compared these with responses in patients with cholera caused by Vibrio cholerae O1 Ogawa. Although vaccinees developed plasma immunoglobulin G (IgG), IgM, IgA antibody and antibody secreting cell (ASC, marker of mucosal response) to Ogawa OSP and LPS 7 days after vaccination, responses were significantly lower than that which occurred after cholera. Similarly, patients recovering from cholera had detectable IgA, IgM, and IgG memory B cell (MBC) responses against OSP and LPS on Day 30 and Day 90, whereas vaccinees only developed IgG responses to OSP 30 days after the second immunization. The markedly lower ASC and MBC responses to OSP and LPS observed among vaccinees might explain, in part, the lower protection of an OCV compared with natural infection.
authors.affiliation: Centre for Vaccine Sciences, International Centre for Diarrhoeal Disease Research, Bangladesh (icddr,b), Dhaka, Bangladesh; NIDDK, LBC, National Institutes of Health, Bethesda, Maryland; Division of Infectious Diseases, Massachusetts General Hospital, Boston, Massachusetts; Departments of Medicine and Pediatrics, Harvard Medical School, Boston, Massachusetts; Department of Biochemistry and Molecular Biology, University of Dhaka, Bangladesh; Department of Microbiology and Immunobiology, Harvard Medical School, Boston, Massachusetts; Department of Immunology and Infectious Diseases, Harvard School of Public Health, Boston, Massachusetts.
authors.forename: Taher
authors.initials: T
authors.lastname: Uddin
authors.forename: Amena
authors.initials: A
authors.lastname: Aktar
authors.forename: Peng
authors.initials: P
authors.lastname: Xu
authors.forename: Russell A
authors.initials: RA
authors.lastname: Johnson
authors.forename: M Arifur
authors.initials: MA
authors.lastname: Rahman
authors.forename: Daniel T
authors.initials: DT
authors.lastname: Leung
authors.forename: Sadia
authors.initials: S
authors.lastname: Afrin
authors.forename: Aklima
authors.initials: A
authors.lastname: Akter
authors.forename: Mohammad Murshid
authors.initials: MM
authors.lastname: Alam
authors.forename: Atiqur
authors.initials: A
authors.lastname: Rahman
authors.forename: Fahima
authors.initials: F
authors.lastname: Chowdhury
authors.forename: Ashraful I
authors.initials: AI
authors.lastname: Khan
authors.forename: Taufiqur Rahman
authors.initials: TR
authors.lastname: Bhuiyan
authors.forename: Meagan K
authors.initials: MK
authors.lastname: Bufano
authors.forename: Rasheduzzaman
authors.initials: R
authors.lastname: Rashu
authors.forename: Yanan
authors.initials: Y
authors.lastname: Yu
authors.forename: Ying
authors.initials: Y
authors.lastname: Wu-Freeman
authors.forename: Jason B
authors.initials: JB
authors.lastname: Harris
authors.forename: Regina C
authors.initials: RC
authors.lastname: LaRocque
authors.forename: Richelle C
authors.initials: RC
authors.lastname: Charles
authors.forename: Pavol
authors.initials: P
authors.lastname: Kováč
authors.forename: Stephen B
authors.initials: SB
authors.lastname: Calderwood
authors.forename: Edward T
authors.initials: ET
authors.lastname: Ryan
authors.forename: Firdausi
authors.initials: F
authors.lastname: Qadri
mesh_terms: D000284:Administration, Oral; D000328:Adult; D000907:Antibodies, Bacterial / Q000097:blood* / Q000276:immunology; D000921:Antibody-Producing Cells / Q000166:cytology / Q000187:drug effects / Q000276:immunology; D001402:B-Lymphocytes / Q000166:cytology / Q000187:drug effects / Q000276:immunology; D001459:Bangladesh / Q000453:epidemiology; D002771:Cholera / Q000276:immunology* / Q000517:prevention & control; D022121:Cholera Vaccines / Q000627:therapeutic use*; D015331:Cohort Studies; D006801:Humans; D007117:Immunization, Secondary; D007070:Immunoglobulin A / Q000097:blood; D007074:Immunoglobulin G / Q000097:blood; D007075:Immunoglobulin M / Q000097:blood; D008070:Lipopolysaccharides / Q000276:immunology*; D019081:O Antigens / Q000276:immunology*; D014611:Vaccination; D015164:Vaccines, Inactivated / Q000627:therapeutic use; D041241:Vibrio cholerae O1 / Q000276:immunology* / Q000302:isolation & purification; D055815:Young Adult
chemical_list: D000907:Antibodies, Bacterial; D022121:Cholera Vaccines; D007070:Immunoglobulin A; D007074:Immunoglobulin G; D007075:Immunoglobulin M; D008070:Lipopolysaccharides; D019081:O Antigens; D015164:Vaccines, Inactivated